AAAAAA
Results: 1-25/37
Authors:
Grunewald, K
Schmidt, W
Unger, C
Hanschmann, G
Citation: K. Grunewald et al., Behavior of glyphosate and aminomethylphosphonic acid (AMPA) in soils and water of reservoir Radeburg II catchment (Saxony/Germany), J PLANT NU, 164(1), 2001, pp. 65-70
Authors:
Kratz, F
Drevs, J
Bing, G
Stockmar, C
Scheuermann, K
Lazar, P
Unger, C
Citation: F. Kratz et al., Development and in vitro efficacy of novel MMP2 and MMP9 specific doxorubicin albumin conjugates, BIOORG MED, 11(15), 2001, pp. 2001-2006
Authors:
Wernhoff, P
Unger, C
Bajtner, E
Burkhardt, H
Holmdahl, R
Citation: P. Wernhoff et al., Identification of conformation-dependent epitopes and V gene selection in the B cell response to type II collagen in the DA rat, INT IMMUNOL, 13(7), 2001, pp. 909-919
Authors:
Hauns, B
Haring, B
Kohler, S
Mross, K
Unger, C
Citation: B. Hauns et al., Phase II study of combined 5-fluorouracil/Ginkgo biloba extract (GBE 761 ONC) therapy in 5-fluorouracil pretreated patients with advanced colorectal cancer, PHYTOTHER R, 15(1), 2001, pp. 34-38
Authors:
Gunsilius, E
Gierlich, T
Mross, K
Gastl, G
Unger, C
Citation: E. Gunsilius et al., Palliative chemotherapy in pretreated patients with advanced cancer: Oral trofosfamide is effective in ovarian carcinoma, CANCER INV, 19(8), 2001, pp. 808-811
Authors:
Beyer, U
Rothen-Rutishauser, B
Unger, C
Wunderli-Allenspach, H
Kratz, F
Citation: U. Beyer et al., Differences in the intracellular distribution of acid-sensitive doxorubicin-protein conjugates in comparison to free and liposomal formulated doxorubicin as shown by confocal microscopy. (vol 18, pg 29, 2001), PHARM RES, 18(5), 2001, pp. 719-719
Authors:
Beyer, U
Rothen-Rutishauser, B
Unger, C
Wunderli-Allenspach, H
Kratz, F
Citation: U. Beyer et al., Differences in the intracellular distribution of acid-sensitive doxorubicin-protein conjugates in comparison to free and liposomal formulated doxorubicin as shown by confocal microscopy, PHARM RES, 18(1), 2001, pp. 29-38
Authors:
Unger, C
Eibl, H
Citation: C. Unger et H. Eibl, Drug development from phospholipids, ONKOLOGIE, 24, 2001, pp. 18-23
Authors:
Arends, J
Unger, C
Citation: J. Arends et C. Unger, Excellent response to gemcitabine in a massively pre-treated woman with extensive cutaneous involvement after recurrence of breast cancer, INV NEW DR, 19(1), 2001, pp. 93-100
Authors:
Gulmezoglu, AM
Villar, J
Ngoc, NTN
Piaggio, G
Carroli, G
Adetoro, L
Abdel-Aleem, H
Cheng, LN
Hofmeyr, GJ
Lumbiganon, P
Unger, C
Prendiville, W
Pinol, A
Elbourne, D
El-Refaey, H
Schulz, KF
Citation: Am. Gulmezoglu et al., WHO multicentre randomised trial of misoprostol in the management of the third stage of labour, LANCET, 358(9283), 2001, pp. 689-695
Authors:
Kraetsch, HG
Unger, C
Wernhoff, P
Schneider, C
Kalden, JR
Holmdahl, R
Burkhardt, H
Citation: Hg. Kraetsch et al., Cartilage-specific autoimmunity in rheumatoid arthritis: characterization of a triple helical B cell epitope in the integrin-binding-domain of collagen type II, EUR J IMMUN, 31(6), 2001, pp. 1666-1673
Authors:
Unger, C
Haring, B
Kruse, A
Thumann, A
Schneider, B
Clemm, C
Weber, B
Clevert, HD
Hockertz, S
Kalousek, MB
Citation: C. Unger et al., Double-blind randomised placebo-controlled phase III study of an E. coli extract plus 5-fluorouracil versus 5-fluorouracil in patients with advanced colorectal cancer, ARZNEI-FOR, 51(4), 2001, pp. 332-338
Authors:
Kratz, F
Roth, T
Fichiner, I
Schumacher, P
Fiebig, HH
Unger, C
Citation: F. Kratz et al., In vitro and in vivo efficacy of acid-sensitive transferrin and albumin doxorubicin conjugates in a human xenograft panel and in the MDA-MB-435 mammacarcinoma model, J DRUG TAR, 8(5), 2000, pp. 305-318
Authors:
Unger, C
Citation: C. Unger, Closure to discussion of "Experience with the connection of large variablespeed compressor drives to HV utility distribution systems", IEEE POW SY, 15(4), 2000, pp. 1466-1466
Authors:
Duchon, G
Schultz, W
Unger, C
Voss, L
Lockley, B
Leuw, J
Citation: G. Duchon et al., Experience with the connection of large variable speed compressor drives to HV utility distribution systems, IEEE POW SY, 15(1), 2000, pp. 455-459
Authors:
Mross, K
Robben-Bathe, P
Edler, L
Baumgart, J
Berdel, WE
Fiebig, H
Unger, C
Citation: K. Mross et al., Phase I clinical trial of a day-1,-3,-5 every 3 weeks schedule with titanocene dichloride (MKT 5) in patients with advanced cancer - A study of the phase I study group of the Association for Medical Oncology (AIO) of the German Cancer Society, ONKOLOGIE, 23(6), 2000, pp. 576-579
Authors:
Moog, R
Brandl, M
Schubert, R
Unger, C
Massing, U
Citation: R. Moog et al., Effect of nucleoside analogues and oligonucleotides on hydrolysis of liposomal phospholipids, INT J PHARM, 206(1-2), 2000, pp. 43-53
Authors:
Kratz, F
Muller-Driver, R
Hofmann, I
Drevs, J
Unger, C
Citation: F. Kratz et al., A novel macromolecular prodrug concept exploiting endogenous serum albuminas a drug carrier for cancer chemotherapy, J MED CHEM, 43(7), 2000, pp. 1253-1256
Authors:
Drevs, J
Hofmann, I
Hugenschmidt, H
Wittig, C
Madjar, H
Muller, M
Wood, J
Martiny-Baron, G
Unger, C
Marme, D
Citation: J. Drevs et al., Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and flood flow in a murine renal cell carcinoma model, CANCER RES, 60(17), 2000, pp. 4819-4824
Authors:
Benzinger, P
Martiny-Baron, G
Reusch, P
Siemeister, G
Kley, JT
Marme, D
Unger, C
Massing, U
Citation: P. Benzinger et al., Targeting of endothelial KDR receptors with 3G2 immunoliposomes in vitro, BBA-BIOMEMB, 1466(1-2), 2000, pp. 71-78
Authors:
Rodrigues, PCA
Beyer, U
Schumacher, P
Roth, T
Fiebig, HH
Unger, C
Messori, L
Orioli, P
Paper, DH
Mulhaupt, R
Kratz, F
Citation: Pca. Rodrigues et al., Acid-sensitive polyethylene glycol conjugates of doxorubicin: Preparation,in vitro efficacy and intracellular distribution, BIO MED CH, 7(11), 1999, pp. 2517-2524
Authors:
Kley, JT
Von Kiedrowski, G
Unger, C
Massing, U
Citation: Jt. Kley et al., Synthesis and PLA(2)-inhibitory properties of 2(R)-acetamidoalkylphosphomethanols with a variable aggregate anchor, BIOORG MED, 9(2), 1999, pp. 261-264
Authors:
Van Cutsem, E
Cunningham, D
Huinink, WWT
Punt, CJA
Alexopoulos, CG
Dirix, L
Symann, M
Blijham, GH
Cholet, P
Fillet, G
Van Groeningen, C
Vannetzel, JM
Levi, F
Panagos, G
Unger, C
Wils, J
Cote, C
Blanc, C
Herait, P
Bleiberg, H
Citation: E. Van Cutsem et al., Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU), EUR J CANC, 35(1), 1999, pp. 54-59
Authors:
Drevs, J
Droll, A
Mross, K
Unger, C
Citation: J. Drevs et al., Angiogenesis inhibition: Drugs in clinical trials, ONKOLOGIE, 22(4), 1999, pp. 282-290
Authors:
Fuxius, S
Unger, C
Mross, K
Citation: S. Fuxius et al., Pulmonary toxicity resulting from treatment with gemcitabine, ONKOLOGIE, 22(2), 1999, pp. 146-149